Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

被引：0
|
作者：
Chao Jing
Junyun Wang
Mingyue Zhu
Zhigang Bai
Baoyi Zhao
Jun Zhang
Jie Yin
Xiaobao Yang
Zongzhi Liu
Zhongtao Zhang
Wei Deng
机构：
[1] Beijing Friendship Hospital,Department of General Surgery, Medical Oncology Group
[2] Capital Medical University,CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics
[3] Beijing Key Laboratory of Cancer Invasion and Metastasis Research & National Clinical Research Center for Digestive Diseases,Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital
[4] Chinese Academy of Sciences/China National Center for Bioinformation,undefined
[5] Chinese Academic of Medical Sciences and Peking Union Medical College,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Immune checkpoint inhibitors; Molecular targeted therapy; Camrelizumab; Apatinib; Advanced gastric cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2597 / 2608
页数：11
相关论文
共 50 条
  • [1] Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    Jing, Chao
    Wang, Junyun
    Zhu, Mingyue
    Bai, Zhigang
    Zhao, Baoyi
    Zhang, Jun
    Yin, Jie
    Yang, Xiaobao
    Liu, Zongzhi
    Zhang, Zhongtao
    Deng, Wei
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (11) : 2597 - 2608
  • [2] Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.
    Jin, Min
    Yang, Shengli
    Liu, Junli
    Zhang, Jieying
    Zhao, Lei
    Yu, Dandan
    Lin, Zhenyu
    Li, Pindong
    Wang, Jing
    Xue, Jun
    Ma, Hong
    Hu, Jianli
    Zhang, Tao
    Liu, Hongli
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 332 - 332
  • [3] Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
    Le Zhang
    Weixue Wang
    Shaohua Ge
    Hongli Li
    Ming Bai
    Jingjing Duan
    Yuchong Yang
    Tao Ning
    Rui Liu
    Xia Wang
    Zhi Ji
    Feixue Wang
    Haiyang Zhang
    Yi Ba
    Ting Deng
    [J]. BMC Cancer, 23
  • [4] Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study
    Zhong, Wen-Jin
    Lin, Jian-An
    Wu, Chu-Ying
    Wang, Jiantian
    Chen, Jun-Xing
    Zheng, Huida
    Ye, Kai
    [J]. CANCER MEDICINE, 2024, 13 (03):
  • [5] Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    Jing, Chao
    Bai, Zhigang
    Zhang, Jun
    Jiang, Hongpeng
    Yang, Xiaobao
    Yan, Shu
    Yin, Jie
    Cai, Jun
    Zhang, Zhongtao
    Deng, Wei
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (05) : 2035 - 2044
  • [6] Sintilimab Plus Apatinib and Chemotherapy as Second-/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
    Zhang, Le
    Wang, Weixue
    Ge, Shaohua
    Li, Hongli
    Bai, Ming
    Duan, Jingjing
    Yang, Yuchong
    Ning, Tao
    Liu, Rui
    Wang, Xia
    Ji, Zhi
    Wang, Feixue
    Zhang, Haiyang
    Ba, Yi
    Deng, Ting
    [J]. BMC CANCER, 2023, 23 (01)
  • [7] Treatment effect of apatinib combined chemotherapy as second-line or above therapy in patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction
    Zhang, Fengli
    Yin, Yanfen
    Ni, Tiantian
    Zhang, Mei
    Zhou, Zhou
    Sun, Xin
    Kuang, Wanghao
    Li, Ping
    [J]. PHARMAZIE, 2020, 75 (08): : 389 - 394
  • [8] Clinical study on the second-line treatment of advanced esophageal squamous cell carcinoma with camrelizumab combined with apatinib and irinotecan: A single-arm, multicenter, phase II study
    He, Yifu
    Li, Chenghui
    Zhang, Fenglin
    Hu, Bing
    Sun, Yubei
    Xia, Xiaoyang
    Zhang, Yanshun
    Wang, Gang
    Xu, Tengyun
    Duan, Aixiong
    Wu, Shusheng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
    Qiu, Zhi-Yuan
    Qin, Rong
    Tian, Guang-Yu
    Zhang, Zhao
    Chen, Meifang
    He, Han
    Xi, Yan
    Wang, Yan
    [J]. MEDICINE, 2021, 100 (17) : E25630
  • [10] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
    Feng, J.
    Shen, B.
    Xu, J.
    Wang, Q.
    Ling, G.
    Mao, Y.
    Cai, M.
    Yang, Y.
    Mei, J.
    Han, Z.
    Wu, Y.
    Shi, L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S913 - S913
12345